After a damaging delay back in 2007, Worthing, U.K.-based Allergy Therapeutics is attempting to revive its Pollinex Quattro Grass allergy vaccine. And now, it has some new funding to help it do just that.
Allergy Therapeutics has turned to public investors for £20 million ($30 million) to move its subcutaneous immunotherapy allergy vaccine through late-phase development. The cash will fund Allergy Therapeutics' attempt to bounce back from the 5-year clinical hold of its U.S. trial program.
Allergy Therapeutics will court a partner to market its Pollinex Quattro Grass vaccine now that the FDA lifted a clinical hold on the grass pollen allergy shot.
Swiss biotech Cytos has scraped together $40 million to advance its pipeline of immunotherapies, giving itself much-needed capital after a cash crunch last summer forced the company to ax most of its staff.
Allergan revealed that it acquired Serica Technologies at the end of last year. Allergan, which makes Botox, plans to operate the company as a subsidiary in Medford, MA. The company makes biomaterial
Allergy Therapeutics was forced to halt its Phase III trial of its Pollinex Quattro ragweed vaccine, but researchers for the company say the data still demonstrates its effectiveness. The study had
Shares of the UK's Allergy Therapeutics surged on the news that its experimental hay fever vaccine--Pollinex Quattro--demonstrated positive results in a crucial Phase III study, which they say was
Shares of Allergy Therapeutics tumbled 22 percent after the FDA froze two late-stage studies of a hayfever vaccine after one of the volunteers in a trial fell ill. The patient reported neurological
London-based Allergy Therapeutics' ragweed allergy vaccine passed a pivotal clinical trial. Researchers said that Pollinex Quattro Ragweed demonstrated significant improvements in symptoms compared